Homoeopathic Medicine causticum 200c

Phase 3Small molecule

Homoeopathic Medicine causticum 200c is one of 19 small molecule programs targeting Enuresis. It is currently in Phase 3.

Indications

Total Trials

Active Trials

Competitors

Pipeline

Status by Indication[3][1]

Indication

EnuresisActive, not recruiting

EnuresisPhase 3

Active, not recruiting

Competition

Competitive Landscape

26 competitors in Enuresis

#DrugCompanyPhaseTrials

Indocin

LLife Extension Foundation Inc.

Approved

1 2

Pitressin

AAultman Health Foundation

Advil

Myrbetriq

2 5

Prozac

VVitae Pharmaceuticals Inc., an Allergan affiliate

Phase 3

2 6

Oxytrol

WWim Janssens

Phase 3

1 7

Circadin

NNeurim Pharmaceuticals Ltd.

Phase 2

1 8

Strattera

MMap77

Phase 1

1 9

Minirin

Ferring

Phase 3

2 10

Homoeopathic Medicine causticum 200c

FFr Muller Homoeopathic Medical College

Phase 3

Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.

Clinical

Trials by Indication[1]

Enuresis1 trial

A Clinical Study on Causticum 200 Centesimal Potency in Primary Enuresis

Unknown status·FFr Muller Homoeopathic Medical College·Phase 3·NCT02154152·50 enrolled

Sources

References

[1]
ClinicalTrials.gov — 1 trial record for Homoeopathic Medicine causticum 200c. U.S. National Library of Medicine, National Institutes of Health.
[2]
ChEMBL — Homoeopathic Medicine causticum 200c compound record. European Bioinformatics Institute (EMBL-EBI).
[3]
Open Targets Platform — Drug–disease associations for Homoeopathic Medicine causticum 200c. EMBL-EBI & Wellcome Sanger Institute.
[4]
SEC EDGAR — Fr Muller Homoeopathic Medical College company filings. U.S. Securities and Exchange Commission.

Details

Drug Info

Quick Facts

Modality: Small molecule[2]
Highest Phase: Phase 3[1]
Company: FFr Muller Homoeopathic Medical College

Homoeopathic Medicine causticum 200c

Status by Indication[3][1]

Competitive Landscape

Trials by Indication[1]

Enuresis1 trial

References

Drug Info

Quick Facts

Related News